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Background and objective: The current systematic review and meta-analysis of 
randomized controlled trials (RCTs) was carried out to assess the influence of curcumin 
intake on weight among patients with metabolic syndrome and related disorders.
Methods: We searched the following databases up until January 2018: MEDLINE, 
EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. The 
relevant data were extracted and evaluated for quality of the studies in accordance with 
the Cochrane risk of bias tool. Data were pooled using the inverse variance method 
and expressed as standardized mean difference (SMD) with 95% confidence intervals 
(95% CI).
Results: Eighteen articles (21 studies) that comprised a total of 1,604 individuals were 
finally included in the meta-analysis. Curcumin intake significantly reduced body mass 
index (BMI) (SMD −0.37; 95% CI, −0.61, −0.13; P < 0.01), weight (SMD −0.23; 95% CI, 
−0.39, −0.06; P < 0.01), waist-circumference (WC) (SMD −0.25; 95% CI, −0.44, −0.05; 
P = 0.01), leptin levels (SMD −0.97; 95% CI, −1.18, −0.75; P < 0.001) and increased 
adiponectin levels (SMD 1.05; 95% CI, 0.23, 1.87; P = 0.01). We found no significant 
effect of curcumin intake on hip ratio (HR) (SMD −0.17; 95% CI, −0.42, 0.08; P = 0.18).
Conclusions: Overall, we have found that curcumin intake among patients with metabolic 
syndrome and related disorders was correlated with a significant reduction in BMI, weight, 
WC, and leptin, and a significant increase in adiponectin levels, but did not affect HR.
Keywords: curcumin, weight loss, meta-analysis, leptin, BMI
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INTRODUCTION
Metabolic syndrome (MetS), obesity, and type 2 diabetes mellitus 
(T2DM) are rapidly increasing in prevalence globally, possibly 
related to poor lifestyle habits, a high calorie diet, low physical 
activity, and smoking (Ewang-Emukowhate et al., 2014). MetS is 
defined as the concurrence of obesity-associated cardiovascular 
risk factors, such as hyperinsulinemia, abdominal obesity, 
hypertriglyceridemia, reduced high-density lipoprotein (HDL)-
cholesterol levels, and/or hypertension (Tune et al., 2017). In parallel 
with the obesity pandemic, MetS is an increasing in prevalence, and 
affects approximately 20% of people in the world (Ofori-Asenso et 
al., 2017). Both MetS and overweight are associated with elevated risk 
of mortality, metabolic disturbances, T2DM, vascular complications 
including atherosclerotic disease and coronary heart disease (CHD) 
(Phillips, 2013; Katsiki et al., 2014; Santilli et al., 2017).
There are some data that have shown that some spices, 
including curcumin may play a key function in the management 
of overweight individuals. Curcumin is a bioactive polyphenol 
component which is found in turmeric rhizomes and is commonly 
referred to as diferuloylmethane (Chainani-Wu, 2003). Clinical 
trials of curcumin on weight- and body mass index (BMI)-
lowering effect have not been systematically evaluated, and the 
results are inconsistent. Di Pierro et al. (Di Pierro et al., 2015), 
have reported that a bioavailable form of curcumin resulted in 
improved weight management in overweight subjects. In addition, 
a significant decline in BMI and liver fat status was observed after 
the intake of 70 mg/day curcumin for 8 weeks among people 
with non-alcoholic fatty liver disease (NAFLD) (Rahmani et al., 
2016). Some other studies have also documented a significant 
effect of curcumin intake on indicators of body composition 
(Chuengsamarn et al., 2012; Panahi et al., 2017a). However, 
anthropometric parameters such as BMI, weight, waist and hip 
circumference, total body fat, and parameters of oxidative stress 
were not affected following the intake of curcumin at a dosage of 
1 g/day in obese people (Mohammadi et al., 2013) and 1 g/day in 
people with MetS (Ghazimoradi et al., 2017). Moreover, another 
study reported no significant effect of curcumin intake on weight 
or BMI (Yang et al., 2014).
It has been suggested that curcumin intake may improve 
weight and metabolic status through increasing basal metabolic 
rate, which may in turn cause increased energy expenditure 
(Bercik et al., 2010). We are aware of no systematic review and 
meta-analysis of randomized controlled trials (RCTs) on the 
effect of curcumin intake on weight loss in people with metabolic 
diseases. This meta-analysis was conducted to summarize the 
existing evidence of RCTs to evaluate the impact of curcumin 
intake on weight loss in patients with MetS and related disorders.
METHODS
Search Strategy and Selection Studies
RCTs were searched systematically using several online databases: 
The Cochrane Library, EMBASE, PubMed, and Web of Science 
databases up until January 2018. For all ongoing trials, we 
conducted searches of two reference databases—Databases of 
International Standard Randomized Controlled Trial Number 
Register and Meta-register for RCTs. RCTs retrieved that have 
investigated the association between curcumin intake and body 
composition using the following Medical Subject Headings 
(MeSH) and search terms: patients (“obese” OR “overweight” 
OR “T2DM” OR “hyperlipidemic” OR “NAFLD” OR “MetS”), 
intervention (“curcumin” OR “turmeric” OR “curcuminoids” 
AND “intake” OR “supplementation”), and outcomes (“body mass 
index [BMI]” OR “body weight” OR “waist-circumference [WC]” 
OR “hip ratio [HR]”OR “leptin” OR “adiponectin”). Two authors 
(MA and ZA) independently conducted a systematic search from 
databases. Reference lists of selected studies and previous review 
article were manually reviewed for additional relevant articles. This 
study was restricted to RCTs published in the English language.
Eligibility Criteria
RCTs were selected using a two-stage process by two researchers 
(MA and RT), independently. In the first stage, researchers screened 
the titles and/or abstracts to include RCTs had eligibility into our 
meta-analysis. In the second, the full texts of eligibility RCTs were 
retrieved to evaluate with more details. The eligibility criteria to 
include into our meta-analysis were human and original trials, 
and the administration of curcumin supplements in intervention 
group, whereas placebo in the comparison group. RCTs that did not 
report the mean changes or mean difference of body composition, 
serum leptin, and adiponectin along with standard deviation (SD) 
for the treatment and control groups, case reports, the abstracts of 
congress without full text; and RCTs that did not achieve at least 
required score of quality assessment, were excluded.
Data Extraction and Quality Assessment
Data extraction and quality assessment of RCTs were carried out 
by two independent authors (ZA and MA), according to standard 
forms in Excel software and the Cochrane Collaboration risk of 
bias tool, respectively. These forms were contained the following 
data: author’s name, publication year, country where the study was 
conducted, study design, dosage of curcumin supplements (mg/
day), the intervention and placebo type, the duration of treatment, 
sample size (intervention and placebo), the mean and standard 
deviation of the body composition, serum leptin, and adiponectin. 
The Cochrane Collaboration risk of bias tool includes the following 
domains related to quality of RCTs: random sequence generation, 
allocation concealment, blinding process and outcome assessment, 
and withdrawal of patients. In the case of discrepancy, resolved by 
discussion with third author (ZA).
Data Analysis
RevMan V.5.3 software (Cochrane Collaboration, Oxford, UK) 
and Stata version 12.0 (Stata Corp., College Station, TX) were 
used for statistical analyses. Heterogeneity was assessed using 
the Cochran’s Q test and I-square statistic. I-square higher than 
50% with P-value <0.05 indicated the existing heterogeneity. 
The inverse variance method and Cohen statistics were used 
for calculation of standardized mean difference (SMD) with 
95% confidence interval (CI). In this study, because of different 
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indications among the included RCTs were conducted a random-
effects model for meta-analysis was used to establish the relation 
between curcumin intake and body composition, leptin, and 
adiponectin levels. However, subgroup analyses were performed 
to evaluate the source of heterogeneity based on suspected 
variables such as dosage of curcumin (≤500 mg/day vs. >500 mg/
day) and the duration of study (≤8 weeks vs. >8 weeks) between 
primary RCTs. In addition, sensitivity analyses were conducted in 
the trials one by one to assess the reliability of the pooled SMDs. 
The existence of potential publication bias was evaluated through 
using Egger’s tests for the primary outcome measure. P-values 
less than 0.05 were considered to be statistically significant.
RESULTS
Administered curcumin in trials included in the present 
meta-analysis was as powder, or extract. A total of 1,163 
studies were identified though our initial literatures search. 
After screening RCTs, 18 articles (21 trials) were determined 
to be appropriate for in the present meta-analysis. The 
flow diagram of the step-by-step study identification and 
selection is shown in Figure 1. Characteristics of RCTs for 
nine curcuminoid supplementation trials, eight curcumin 
supplementation trials, and one nano-curcumin trial included 
in this meta-analysis are presented in Table 1. RCTs were 
FIGURE 1 | Literature search and review flowchart for selection of studies.
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TABLE 1 | The characteristics of included randomized controlled trials (RCTs).
Authors (Ref) Publication 
year
Country Intervention/
control
(sample size)
Duration
(week)
Dosage (mg/day) Patients Type of intervention Mean age 
(control/
intervention)
Adab et al. (2013) 2013 Iran 39/36 8 2,100 mg of turmeric powder 
daily
Hyperlipidemic patients 
with type 2 diabetes 
mellitus
Turmeric powder 55.66 ± 8.64, 
54.76 ± 6.00
Amin et al. (2015) 2015 Pakistan 63/63 8 2.4 g/day
(800 mg in three capsule)
Metabolic syndrome Powdered rhizome of Curcuma 
longa (turmeric)
41.57 ± 12.8, 
42.4 ± 13.7
Chuengsamarn et al. (2014) 2014 Thailand 107/106 24 Curcuminoid content of 250 mg 
(six capsules daily)
Type 2 diabetes mellitus Curcumin capsule (rhizomes of 
turmeric)
59.58 ± 10.70, 
59.16 ± 10.96
Chuengsamarn et al. (2012) 2012 Thailand 117/117 36 Curcuminoid content of 250 mg 
(six capsules daily)
Type 2 diabetes mellitus Dried rhizomes of turmeric 
(Curcuma longa Linn).
57.93 ± 12.76, 
56.95 ± 11.89
Di Pierro et al. (2015) 2015 Italy 22/22 8 800 mg/daily Metabolic syndrome 
(overweight)
Curcumin-based product-
Curcuma longa extract
41.85 ± 15.91, 
39.10 ± 16.8
Ismail et al. (2016) 2016 Egypt 15/14 4 One capsule containing 500 mg 
curcumin
Pediatrics obese subjects Curcuminoids are extracted from 
turmeric (Curcuma longa root)
14.7 ± 4.52
Ismail et al. (2016) 2016 Egypt 15/14 4 One capsule containing 500 mg 
curcumin
Adults obese subjects Curcuminoids are extracted from 
turmeric (Curcuma longa root)
37.55 ± 9.93
Ismail et al. (2014) 2014 Egypt 14/11 4 One capsule containing 500 mg 
curcumin
Obese children Curcuminoids are extracted from 
turmeric (Curcuma longa root)
15.57 ± 5.79, 
16.53 ± 8.7
Kocher et al. (2016) 2016 Germany 42/42 6 294 mg curcuminoids per day 
(as micelles)
Hyperlipidemic individuals 
(overweight)
Curcumin powder 51.19 ± 17.61
Mohammadi et al. (2017) 2017 Iran 36/36 6 200 mg pure curcumin per day Metabolic syndrome Curcumin capsule 38.59 ± 10.28, 
37.52 ± 9.47
Mohammadi et al. (2013) 2013 Iran 15/15 4 500 mg C3 capsules containing 
500 mg (1,000 mg/day)
Obese patients Curcuminoids plus 5 mg 
BioPerine
37.9 ± 12.7, 
39.0 ± 9.0
Nieman et al. (2012) 2012 USA 30/30 4 TM (2.8 g/day) or ~112 mg 
curcumin
Overweight females Turmeric capsule 55.7 ± 1.4
Panahi et al. (2017b) 2017 Iran 44/43 8 500 mg C3 capsules containing 
500 mg (1,000 mg/day)
Non-alcoholic fatty liver 
disease
Curcumin capsule (phytosomal 
form)
47.21 ± 10.29, 
44.98 ± 12.59
Panahi et al. (2017a) 2017 Iran 50/50 8 500 mg C3 capsules containing 
500 mg (1,000 mg/day)
Type 2 diabetes mellitus Curcuminoids plus 5 mg bioperine 41 ± 7, 43 ± 8
Panahi et al. (2016) 2016 Iran 50/50 8 500 mg C3 capsules containing 
500 mg (1,000 mg/day)
Metabolic syndrome Curcuminoids plus 5 mg bioperine 43.46 ± 9.70, 
44.80 ± 8.67
Rahimi et al. (2016) 2016 Iran 35/35 12 80 mg/day Type 2 diabetes mellitus Nano-curcumin 60.95 ± 10.77, 
56.34 ± 11.17
Rahmani et al. (2016) 2016 Iran 37/40 8 500 mg/day Non-alcoholic fatty liver 
disease
Curcumin powder 48.95 ± 9.78, 
46.37 ± 11.57
Sahebkar et al. (2013) 2013 Iran 15/15 4 500 mg C3 capsules containing 
500 mg (1,000 mg/day)
Obese individuals Curcuminoids plus 5 mg bioperine 38.43 ± 10.84
Yang et al. (2014) 2014 Taiwan 30/29 12 Curcumin extract capsule (630 
mg three times daily) turmeric 
(C. longa) extract
Metabolic syndrome 
(overweight)
Curcumin capsule 59.61 ± 14.09, 
59.03 ± 10.10
TM, tumeric.
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published from 2012 to 2017. In total, the meta-analysis was 
conducted on 1,646 participants with various total sample size 
from 25 to 234 persons. Fifteen articles were double-blind, 
and three studies were single-blind. 14 articles used parallel 
design, and four used crossover design. Fourteen trials have 
showed changes on BMI, 15 on body weight, 9 on WC, 5 on 
HR, 4 on leptin, and 5 on adiponectin. Total daily dose of 
curcumin intake or curcumin consumption varied between 70 
and 2,400 mg/day. The duration of treatment among studies 
was between 4 and 36 weeks. The methodological quality of 
included trials into present meta-analysis was evaluated using 
the Cochrane Collaboration risk of bias tool based on authors’ 
judgments about each risk of bias item for each included study 
is shown in Figure 2.
Pooled Effects of Curcumin 
Supplementation on Body Composition
Figure 3 shows the forest plots for the effect of curcumin 
supplementation on body composition. Curcumin resulted a 
significant reduction in BMI (SMD −0.37; 95% CI, −0.61, −0.13; 
P < 0.01), weight (SMD −0.23; 95% CI, −0.39, −0.06; P < 0.01), 
and WC levels (SMD −0.25; 95% CI, −0.44, −0.05; P = 0.01). We 
observed no significant effect of curcumin on HR (SMD −0.17; 
95% CI, −0.42, 0.08; P = 0.18).
All meta-analyses of the study subject included RCTs with 
data before and after the intervention and control groups are 
presented in Table 2.
Subgroup analyses for all body composition were conducted 
based on suspected variables for heterogeneity including dosage 
of curcumin and duration of study. However, the results of 
subgroup analyses showed that the reduction of heterogeneity 
was found in some of specific strata of suspected variables 
(Table 3).
In sensitivity analysis, to assess the impact of one by one 
of all the included studies on the strength of relation between 
curcumin intake and body composition, the pooled SMD was 
summarized pre and post excluding each RCT from the meta-
analysis. After excluding each study from the analyses, we 
observed no considerable difference between the pre- and post-
sensitivity pooled SMD for BMI, BW, and HR (Table 4). But after 
omitting the data from the study of Panahi et al. (2017b) for WC, 
we found that there was significant impact between pre- (SMD 
−0.25; 95% CI, −0.44, −0.05) and post- (SMD −0.20; 95% CI, 
−0.42, 0.00) sensitivity pooled SMD for their body compositions.
Pooled Effects of Curcumin on Adipokines
The effects of curcumin intake on serum adipokines are presented 
in Figure 4. The results showed that curcumin intake among 
FIGURE 2 | The methodological quality of included studies on effect of curcumin on body composition and adipokines based on review authors’ judgments about 
each risk of bias item presented as percentages across all included studies (A) and each risk of bias item for each included study (B).
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FIGURE 3 | Continued
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FIGURE 3 | Meta-analysis body composition standardized mean difference estimates for (A) BMI, (B) for weight, (C) for waist-circumference (WC), and (D) for hip 
ratio (HR) in curcumin supplements and placebo groups (CI = 95%).
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TABLE 2 | The effects of curcumin intake on body mass index (BMI), weight, and body fat reduction based on subgroup analysis.
Variable Number of 
study
Standardized 
mean 
difference
CI 95% Heterogeneity
I2 (%) Q P-value
Body 
composition
BMI Intervention group (after vs. before) 14 −0.18 −0.31, −0.05 0.0 4.87 0.97
Placebo group (after vs. before) 14 −0.01 −0.14, 0.12 0.0 1.55 0.99
Change intervention group vs. 
placebo group
14 −0.37 −0.61, −0.13 69.7 42.95 <0.001
Body weight Intervention group (after vs. before) 15 −0.14 −0.26, −0.02 0.0 3.91 0.99
Placebo group (after vs. before) 15 0.04 −0.08, 0.16 0.0 3.25 0.99
Change intervention group vs. 
placebo group
15 −0.23 −0.39, −0.06 45.7 25.80 0.02
WC Intervention group (after vs. before) 9 −0.27 −0.41, −0.14 0.0 4.26 0.83
Placebo group (after vs. before) 9 −0.00 −0.14, 0.13 0.0 6.50 0.59
Change intervention group vs. 
placebo group
9 −0.25 −0.44, −0.05 42.1 13.82 0.08
HR Intervention group (after vs. before) 5 −0.24 −0.48, 0.01 0.0 0.49 0.97
Placebo group (after vs. before) 5 −0.10 −0.34, 0.15 0.0 1.02 0.90
Change intervention group vs. 
placebo group
5 −0.17 −0.42, 0.08 0.0 1.69 0.79
Adipokines Leptin Intervention group (after vs. before) 4 −1.36 −1.77, −0.95 58.9 7.29 0.06
Placebo group (after vs. before) 4 −0.08 −0.28, 0.13 0.0 1.98 0.57
Change intervention group vs. 
placebo group
4 −0.97 −1.18, −0.75 0.0 1.81 0.61
Adiponectin Intervention group (after vs. before) 5 1.22 0.17, 2.27 96.4 111.23 <0.001
Placebo group (after vs. before) 5 0.23 −0.29, 0.75 87.7 32.46 <0.001
Change intervention group vs. 
placebo group
5 1.05 0.23, 1.87 94.5 72.30 <0.001
WC, waist-circumference; HR, hip ratio.
TABLE 3 | The effects of curcumin supplementation on body composition based on subgroup analysis.
Variable Number 
of SMD 
included
Subgroups Pooled 
effect 
estimate
95% CI I2 (%) Overall 
I2 (%)
BMI Dosage of curcumin (mg/day) 4 ≤500 (mg/day) −0.46 −0.93, 0.01 79.2 69.7
10 >500 (mg/day) −0.33 −0.63, −0.03 68.2
Duration of study (week) 10 ≤8 weeks −0.42 −0.69, −0.14 72.1
4 >8 weeks −0.24 −0.79, 0.32 71.1
Body weight Dosage of curcumin (mg/day) 5 ≤500 (mg/day) −0.43 −0.85, −0.00 78.1 45.7
10  >500 (mg/day) −0.19 −0.33, −0.04 0.0
Duration of study (week) 11 ≤8 weeks −0.25 −0.46, − 0.04 54.9
4 >8 weeks −0.22 −0.47, 0.03 52.4
WC Dosage of curcumin (mg/day) 2 ≤500 (mg/day) 0.07 −0.33, 0.46 0.0 42.1
7  >500 (mg/day) −0.31 −0.51, −0.10 41.4
Duration of study (week) 5 ≤8 weeks −0.15 −0.36, 0.07 5.1
4 >8 weeks −0.34 −0.64, −0.04 51.6
HR Dosage of curcumin (mg/day) 1 ≤500 (mg/day) 0.11 −0.68, 0.90 - 0.0
4 >500 (mg/day) −0.20 −0.46, 0.06 0.0
Duration of study (week) 3 ≤8 weeks −0.23 −0.51, 0.06 0.0
2 >8 weeks 0.02 −0.49, 0.53 0.0
Leptin Dosage of curcumin (mg/day) 2 ≤500 (mg/day) −0.86 −1.42, −0.30 6.0 0.0
2 >500 (mg/day) −0.99 −1.22, −0.75 0.0
Duration of study (week) 3 ≤8 weeks −0.86 −1.19, −0.53 0.0
1 >8 weeks −1.05 −1.34, −0.76 -
Adiponectin Dosage of curcumin (mg/day) 2 ≤500 (mg/day) 0.65 −0.11, 1.41 50.4 94.5
3  >500 (mg/day) 1.28 0.15, 2.41 97.1
Duration of study (week) 3 ≤8 weeks 0.95 0.27, 1.63 70.3
2 >8 weeks 1.23 −0.49, 2.94 98.5
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individuals with metabolic diseases significantly reduced leptin 
(SMD −0.97; 95% CI, −1.18, −0.75; P < 0.001) and increased 
adiponectin levels (SMD 1.05; 95% CI, 0.23, 1.87; P = 0.01).
According to findings of subgroup analyses, the reduction 
of heterogeneity was found in some of specific strata of 
suspected variables which the details of subgroup analyses were 
demonstrated in Table 3.
Sensitivity analysis was performed, and the results for 
serum leptin remained consistent with the pooled SMD. 
However, the lower and higher pooled SMD for serum leptin 
in the sensitivity analysis were −1.01 (95% CI: −1.26, −0.75) 
after omitting the data from Panahi et al. (2016) −0.85 (−1.18, 
−0.53) and after omitting the data from Chuengsamarn et al. 
(2014), respectively.
For serum adiponectin, we found that there was significant 
impact between pre- (SMD 1.05; 95% CI, 0.23, 1.87) and 
post- (SMD 0.95; 95% CI, −0.09, 2.01) sensitivity pooled SMD 
after omitting the data from the study of Panahi et al. (2016) 
(Table 4).
Publication Bias
Egger’s regression test was applied to detect potential 
publication bias among the included studies in our meta-
analyses. The findings of Egger’s regression test exhibited that 
no significant publication bias for meta-analyses estimating 
the effects of curcumin intake on BMI (B = 0.38, P = 0.84), 
BW (B = 0.28, P = 0.79), WC (B = 1.86, P = 0.11), serum 
leptin (B = 0.75, P = 0.56), and serum adiponectin (B = 1.14, 
P = 0.85).
But, there was evidence of the possible publication bias on 
the effects of curcumin intake on HR (B = 1.77, P < 0.01). 
Therefore, we used nonparametric method (Duval and 
Tweedie) to include the results of censored studies. The results 
indicated that summary effect sizes changed significantly for 
HR between before (SMD 0.17; 95% CI, −0.42, 0.08) and after 
(SMD −0.24; 95% CI, −0.46, −0.02) including the results of 
censored studies.
DISCUSSION
Our meta-analysis is the first report of the impact of curcumin 
intake on BMI, weight, body fat, leptin and adiponectin 
levels, and demonstrated that curcumin intake was correlated 
with a significantly decline in BMI, weight, WC, and leptin, 
and a significant increase in adiponectin levels, but did not 
affect HR.
MetS and obesity are associated with several metabolic and 
non-metabolic disorders such as CHD, T2DM, and certain types 
of cancer (Kromhout, 1983; Lynch et al., 2009). The current 
meta-analysis indicated that curcumin consumption resulted 
in a detectable reduction in BMI, weight, WC, and leptin, and 
a significant increase in adiponectin levels, but did not affect 
HR. Prior studies have evidenced that some spices may play 
a role in the management of obesity. In a meta-analysis by 
Hursel et al. (2011), it was seen that catechin-caffeine mixtures 
or a  caffeine-only administration significantly induced energy 
expenditure.  In addition, the intake of  capsaicinoids decreased 
body weight  through reductions in  energy  intake (Whiting et 
al., 2014). In another meta-analysis study, taking ginger by obese 
people decreased body weight, WC, HR, fasting glucose, and 
insulin resistance, and increased HDL-cholesterol, whereas did 
not influence insulin, BMI, triglycerides, total- and low-density 
lipoprotein (LDL)-cholesterol concentrations (Maharlouei et al., 
2018). Moreover, catechins intake reduced  weight  as well as 
maintained  weight  after a period of weight loss (Hursel et al., 
2009). On the other hand, some investigators have proved the 
useful effects of curcumin on the management of obesity. For 
example, a detrimental decline in BMI and liver fat status was 
seen after the consumption of 70 mg/day curcumin for 8 weeks 
in individuals with non-alcoholic fatty liver disease (NAFLD) 
(Rahmani et al., 2016). Taking nano-curcumin at a dose of 
800 mg/day for 3 months by people with T2DM reduced BMI, 
hemoglobin A1c (HbA1c), fasting glucose, and triglycerides 
levels (Rahimi et al., 2016). However, some studies did not 
observe such useful effects of curcumin intake on BMI and body 
weight. For instance, anthropometric parameters such as BMI, 
TABLE 4 | The association between curcumin supplementation and body composition using sensitivity analysis.
Variable Pre-sensitivity analysis Upper and 
lower of 
effect size
Post-sensitivity analysis
No. of 
studies 
included
Pooled SMD
(random effect)
95% CI Pooled SMD
(random effect)
95% CI Excluded studies
BMI 14 −0.37 −0.61, −0.13 Upper −0.30 −0.51, −0.08 Panahi #2
Lower −0.41 −0.66, −0.17 Kocher
Body weight 15 −0.23 −0.39, −0.06 Upper −0.17 −0.29, −0.05 Rahmani
Lower −0.25 −0.42, −0.08 Kocher
WC 9 −0.25 −0.44, −0.05 Upper −0.17 −0.33, −0.01 Churngsamarn (2012)
Lower −0.20 −0.42, 0.00 Panahi #1
HR 5 −0.17 −0.42, 0.08 Upper −0.02 −0.37, 0.31 Amin
Lower −0.20 −0.46, 0.06 Mohammadi (b)
Leptin 4 −0.97 −1.18, −0.75 Upper −0.85 −1.18, −0.53 Churngsamarn (2014)
Lower −1.01 −1.26, −0.75 Panahi 
Adiponectin 5 1.05 0.23, 1.87 Upper 1.26 0.51, 2.00 Churngsamarn (2012)
Lower 0.95 −0.09, 2.01 Panahi 
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weight, waist and hip circumference, and total body fat did not 
affect after the intake of curcumin at a dosage of 1 g/day in obese 
people (Mohammadi et al., 2013).
Inhibiting key transcriptional proteins related to adipogenesis 
may result in weight reduction and decreasing adipose tissue 
(Ejaz et al., 2009). In an animal study, suppressing angiogenesis 
in adipose tissue, downregulating preadipocyte differentiation, 
and upregulating adipocyte energy metabolism and apoptosis 
by curcumin intake led to lower body fat (Ejaz et al., 
2009). Curcumin intake also up-regulates the gene expression 
of phosphorylated AMP-activated protein kinase (AMPK), 
perhaps via liver kinase B1, and this activated AMPK, which 
subsequently can function as a sirtuin 1 (SIRT1) activator 
(Binion et al., 2008). It would be predicted that activators of 
SIRT1 in adipose tissue would decrease inflammatory cytokine 
secretion, reduce macrophage infiltration, and improve insulin 
FIGURE 4 | Meta-analysis adipokines standardized mean differences estimates for (A) leptin and for (B) adiponectin in curcumin supplements and placebo groups 
(CI = 95%).
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sensitivity (Yoshizaki et al., 2010). In addition, inhibiting 
pro-inflammatory cytokines such as tumor necrosis factor-α, 
plasminogen activator inhibitor type-1, and monocyte 
chemoattractant protein-1 following the intake of curcumin 
may justify its effect on weight loss (Bradford, 2013). Reducing 
BMI, weight, and total fat, and increasing percentage of 
lean mass are extremely useful toward increased insulin 
sensitivity and decreased risk of cardiovascular disturbances 
in obese individuals (Weisberg et al., 2008). Furthermore, 
curcumin down-regulates Janus Kinase enzyme which has 
been documented to have a fundamental function in obesity 
pathogenesis (Wang et al., 2009). Curcumin may also suppress 
11beta-hydroxysteroid dehydrogenase enzyme which activates 
cortisol (Hu et al., 2013). Higher levels of cortisol in adipocytes 
induces central obesity (Kumari et al., 2010). In addition, 
curcumin reduces weight and BMI through the inhibition of 
adipocyte differentiation in the early stages via suppression 
of transcription factor peroxisome proliferator-activated 
receptor gamma (PPAR-γ) and by increasing monophosphate-
activated protein kinase and consequently lipolysis (Lee et 
al., 2009). Curcumin may increase adiponectin expression 
in adipocyte through increased PPAR-γ expression (Dong 
et al., 2007). Activation of PPAR-γ results in enhanced 
insulin sensitivity in skeletal muscle and liver, and improves 
the secretory profiles of adipose tissue, favoring release of 
insulin-sensitizing adipokines including adiponectin, and 
decreasing inflammatory cytokines (Astapova and Leff, 
2012). The inhibitory effects of curcumin on expression of 
estrogen receptor alpha (ERα) and the increasing of ERβ/
ERα  gene  expression ratio also would result in a significant 
decrease in expression of both leptin and leptin receptor 
(Nejati-Koshki et al., 2014).
In view of the existing evidence, curcumin intake could 
be suggested as an effective supplement to be used for the 
management of MetS. A particular advantage of curcumin is 
their safety. Curcuminoids have been approved by US FDA as 
“generally recognized as safe” (GRAS), and their good tolerability 
and toxicity profile has been documented by several clinical 
trials (Sahebkar et al., 2013; Panahi et al., 2014; Mohammadi 
et al., 2017), even at high doses between 4,000 and 8,000 mg/day 
(Basnet and Skalko-Basnet, 2011).
Limitations
The main limitation of the current study is that most of the included 
studies were performed with unformulated curcumin, which has 
low bioavailability due to poor absorption, rapid metabolism, and 
rapid removal from the body. Also, included studies had a low 
to moderate methodological quality. Furthermore, significant 
heterogeneity among included studies might be explained by 
the use of different methodologies, various dosages of curcumin 
used and in different durations, and evaluation of different 
populations. There were few eligible RCTs and a modest number 
of participants to be included in the meta-analysis to analyze the 
clinical effectiveness of curcumin on weight loss.
CONCLUSIONS
Overall, the current meta-analysis demonstrated that curcumin 
intake significantly decreased BMI, weight, WC, and leptin, and 
significantly increased adiponectin levels, but did not affect HR.
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